City

Houston (1)

Nashville (1)

Condition

Recurrent Central Nervous System Lymphoma (2)

Refractory Central Nervous System Lymphoma (2)

Central Nervous System B-Cell Non-Hodgkin Lymphoma (1)

Recurrent Diffuse Large B-Cell Lymphoma (1)

Refractory Diffuse Large B-Cell Lymphoma (1)

Overall Status

Recruiting (1)

Terminated (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

M.D. Anderson Cancer Center (1)

Vanderbilt-Ingram Cancer Center (1)

Collaborator

National Cancer Institute (NCI) (2)

Bristol-Myers Squibb (1)

Intervention

nivolumab (2)

ibrutinib (1)

lenalidomide (1)

rituximab (1)

Study Documents

Intervention Type

biological (2)

drug (2)

Funder Type

Other (2)

Study Type

Interventional (2)

recurrent central nervous system lymphoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting

Central Nervous System B-Cell Non-Hodgkin Lymphoma
+2 more

Ibrutinib
Nivolumab

Houston, Texas

M D Anderson Cancer Center

Dec 13, 2022

Recurrent CNS Lymphoma, Recurrent DLBCL, Refractory CNS Lymphoma Trial in Nashville (Nivolumab, Rituximab, Lenalidomide)

Terminated

Recurrent Central Nervous System Lymphoma
+3 more

Nivolumab
+2 more

Nashville, Tennessee

Vanderbilt-Ingram Cancer Center

Apr 23, 2019